Testing effectiveness (Phase 2)Looking for participantsNCT06413992
What this trial is testing
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Who this might be right for
Endometrial CarcinomaTP53 MutationRecurrent or Metastatic
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 117